Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863801 | 0.88 | ALDH1A1 (0.50) | MEN1KMT2ANPSR1LMNANPC1 | |
| SCHEMBL2856717 | 0.83 | NPSR1 (0.46) | MEN1KMT2ANPSR1LMNAPOLB | |
| SCHEMBL2866314 | 0.81 | KMT2A (0.46) | MEN1KMT2ALMNANPC1POLB | |
| SCHEMBL2865427 | 0.78 | HTR2C (0.33) | KMT2ANR3C2NPSR1POLBALDH1A1 | |
| SCHEMBL2864543 | 0.77 | POLB (0.38) | MEN1KMT2ANPSR1LMNANPC1 | |
| SCHEMBL2870723 | 0.74 | MEN1 (0.39) | MEN1KMT2ANPSR1NPC1MAOB | |
| SCHEMBL2864826 | 0.74 | F10 (0.40) | NPSR1LMNAPOLBRAB9AALDH1A1 | |
| SCHEMBL2863274 | 0.72 | ALDH1A1 (0.41) | MEN1KMT2ANPSR1NPC1POLB | |
| SCHEMBL2861932 | 0.72 | ALDH1A1 (0.39) | MEN1KMT2ANPSR1LMNAALDH1A1 | |
| SCHEMBL2862405 | 0.72 | EP300 (0.47) | MEN1KMT2ALMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | MEN1 4666/4885KMT2A 922/4885NR3C2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.